{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:58:45Z","timestamp":1791845925092,"version":"4.3.4"},"reference-count":116,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL07741"],"award-info":[{"award-number":["T32HL07741"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,4,18]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic with significant morbidity and mortality since first appearing in Wuhan, China, in late 2019. As many countries are grappling with the onset of their epidemics, pharmacotherapeutics remain lacking. The window of opportunity to mitigate downstream morbidity and mortality is narrow but remains open. The renin\u2013angiotensin\u2013aldosterone system (RAAS) is crucial to the homeostasis of both the cardiovascular and respiratory systems. Importantly, SARS-CoV-2 utilises and interrupts this pathway directly, which could be described as the renin\u2013angiotensin\u2013aldosterone\u2013SARS-CoV (RAAS\u2013SCoV) axis. There exists significant controversy and confusion surrounding how anti-hypertensive agents might function along this pathway. This review explores the current state of knowledge regarding the RAAS\u2013SCoV axis (informed by prior studies of SARS-CoV), how this relates to our currently evolving pandemic, and how these insights might guide our next steps in an evidence-based manner.<\/jats:p><\/jats:sec><jats:sec><jats:title>Observations<\/jats:title><jats:p>This review discusses the role of the RAAS\u2013SCoV axis in acute lung injury and the effects, risks and benefits of pharmacological modification of this axis. There may be an opportunity to leverage the different aspects of RAAS inhibitors to mitigate indirect viral-induced lung injury. Concerns have been raised that such modulation might exacerbate the disease. While relevant preclinical, experimental models to date favour a protective effect of RAAS\u2013SCoV axis inhibition on both lung injury and survival, clinical data related to the role of RAAS modulation in the setting of SARS-CoV-2 remain limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Proposed interventions for SARS-CoV-2 predominantly focus on viral microbiology and aim to inhibit viral cellular injury. While these therapies are promising, immediate use may not be feasible, and the time window of their efficacy remains a major unanswered question. An alternative approach is the modulation of the specific downstream pathophysiological effects caused by the virus that lead to morbidity and mortality. We propose a preponderance of evidence that supports clinical equipoise regarding the efficacy of RAAS-based interventions, and the imminent need for a multisite randomised controlled clinical trial to evaluate the inhibition of the RAAS\u2013SCoV axis on acute lung injury in COVID-19.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.00912-2020","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:40:43Z","timestamp":1588009243000},"page":"2000912","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":131,"title":["Understanding the renin\u2013angiotensin\u2013aldosterone\u2013SARS-CoV axis: a comprehensive review"],"prefix":"10.1183","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0292-0594","authenticated-orcid":false,"given":"Nicholas E.","family":"Ingraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdo G.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Reilkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2917-5237","authenticated-orcid":false,"given":"Tamara","family":"Bezdicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Schacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey G.","family":"Chipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Tignanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Puskarich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"2024102101354455000_56.1.2000912.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"2024102101354455000_56.1.2000912.2","unstructured":"Johns Hopkins University Center for Systems Science and Engineering . Coronavirus COVID-19 (2019-nCoV). www.arcgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40299423467b48e9ecf6"},{"key":"2024102101354455000_56.1.2000912.3","unstructured":"World Health Organization . Coronavirus disease (COVID-2019) situation reports. www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports"},{"key":"2024102101354455000_56.1.2000912.4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jmv.25748","article-title":"Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures","volume":"92","author":"Wang","year":"2020","journal-title":"J Med Virol"},{"key":"2024102101354455000_56.1.2000912.5","doi-asserted-by":"crossref","unstructured":"Rajgor DD , Lee MH , Archuleta S , et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis 2020; in press [ https:\/\/doi.org\/10.1016\/S1473-3099(20)30244-9 ].","DOI":"10.1016\/S1473-3099(20)30244-9"},{"key":"2024102101354455000_56.1.2000912.6","unstructured":"WHO-China Joint Mission . Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) . www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report.pdf Date last updated: 24 February 2020."},{"key":"2024102101354455000_56.1.2000912.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.050"},{"key":"2024102101354455000_56.1.2000912.8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/CM9.0000000000000775","article-title":"Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease","volume":"133","author":"Liu","year":"2020","journal-title":"Chin Med J"},{"key":"2024102101354455000_56.1.2000912.9","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2024102101354455000_56.1.2000912.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05985-9"},{"key":"2024102101354455000_56.1.2000912.11","doi-asserted-by":"crossref","first-page":"e0108","DOI":"10.1097\/CCE.0000000000000108","article-title":"Fact versus science fiction: fighting coronavirus disease 2019 requires the wisdom to know the difference","volume":"2","author":"Ingraham","year":"2020","journal-title":"Crit Care Explor"},{"key":"2024102101354455000_56.1.2000912.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-006-0094-9"},{"key":"2024102101354455000_56.1.2000912.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"2024102101354455000_56.1.2000912.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"2024102101354455000_56.1.2000912.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104260"},{"key":"2024102101354455000_56.1.2000912.16","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.043919-0"},{"key":"2024102101354455000_56.1.2000912.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267"},{"key":"2024102101354455000_56.1.2000912.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145"},{"key":"2024102101354455000_56.1.2000912.19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01248-09"},{"key":"2024102101354455000_56.1.2000912.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711241105"},{"key":"2024102101354455000_56.1.2000912.21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00315-07"},{"key":"2024102101354455000_56.1.2000912.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"2024102101354455000_56.1.2000912.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature03712"},{"key":"2024102101354455000_56.1.2000912.24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.23.14614-14621.2005"},{"key":"2024102101354455000_56.1.2000912.25","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00071.2009"},{"key":"2024102101354455000_56.1.2000912.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.17.2203"},{"key":"2024102101354455000_56.1.2000912.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2016.81"},{"key":"2024102101354455000_56.1.2000912.28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/v11010059","article-title":"From SARS to MERS, thrusting coronaviruses into the spotlight","volume":"11","author":"Song","year":"2019","journal-title":"Viruses"},{"key":"2024102101354455000_56.1.2000912.29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: a systematic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J Med Virol"},{"key":"2024102101354455000_56.1.2000912.30","doi-asserted-by":"crossref","unstructured":"Li H , Zhou Y , Zhang M , et al. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother 2020; in press [ https:\/\/doi.org\/10.1128\/AAC.00483-20 ].","DOI":"10.1128\/AAC.00483-20"},{"key":"2024102101354455000_56.1.2000912.31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jmv.25750","article-title":"Transmission dynamics of the COVID-19 outbreak and effectiveness of government interventions: a data-driven analysis","volume":"92","author":"Fang","year":"2020","journal-title":"J Med Virol"},{"key":"2024102101354455000_56.1.2000912.32","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa020"},{"key":"2024102101354455000_56.1.2000912.33","doi-asserted-by":"crossref","unstructured":"Gurwitz D . Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020; in press [ https:\/\/doi.org\/10.1002\/ddr.21656 ].","DOI":"10.1002\/ddr.21656"},{"key":"2024102101354455000_56.1.2000912.34","unstructured":"Henry B . COVID-19 induced renin\u2013angiotensin system (RAS) imbalance may drive acute lung injury: the evidence and therapeutic options. BMJ 2020; rapid response [ www.bmj.com\/content\/368\/bmj.m406\/rr-19 ]."},{"key":"2024102101354455000_56.1.2000912.35","first-page":"219","article-title":"[Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia]","volume":"43","author":"Sun","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"2024102101354455000_56.1.2000912.36","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S2213-2600(20)30153-3","article-title":"Antihypertensive drugs and risk of COVID-19?","volume":"8","author":"Tignanelli","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102101354455000_56.1.2000912.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0360-5"},{"key":"2024102101354455000_56.1.2000912.38","unstructured":"Sommerstein R . Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ 2020; rapid response [ www.bmj.com\/content\/368\/bmj.m810\/rr-2 ]."},{"key":"2024102101354455000_56.1.2000912.39","unstructured":"Garami AR . Preventing a COVID-19 pandemic: is there a magic bullet to save COVID-19 patients? We can give it a try! BMJ 2020; rapid response [ www.bmj.com\/content\/368\/bmj.m810\/rr-24 ]."},{"key":"2024102101354455000_56.1.2000912.40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.12688\/f1000research.9692.1","article-title":"Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy","volume":"6","author":"Ghazi","year":"2017","journal-title":"F1000Res"},{"key":"2024102101354455000_56.1.2000912.41","doi-asserted-by":"crossref","first-page":"256294","DOI":"10.1155\/2012\/256294","article-title":"Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease","volume":"2012","author":"Tikellis","year":"2012","journal-title":"Int J Pept"},{"key":"2024102101354455000_56.1.2000912.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.06.011"},{"key":"2024102101354455000_56.1.2000912.43","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-200210000-00006"},{"key":"2024102101354455000_56.1.2000912.44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1002101"},{"key":"2024102101354455000_56.1.2000912.45","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4240-7"},{"key":"2024102101354455000_56.1.2000912.46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13054-017-1882-z","article-title":"Recombinant human ACE2: acing out angiotensin II in ARDS therapy","volume":"21","author":"Zhang","year":"2017","journal-title":"Crit Care"},{"key":"2024102101354455000_56.1.2000912.47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1507\/endocrj.EJ17-0477","article-title":"Angiotensin II aggravates lipopolysaccharide induced human pulmonary microvascular endothelial cells permeability in high glucose status","volume":"65","author":"Chen","year":"2018","journal-title":"Endocr J"},{"key":"2024102101354455000_56.1.2000912.48","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033455477"},{"key":"2024102101354455000_56.1.2000912.49","doi-asserted-by":"publisher","DOI":"10.1002\/path.2987"},{"key":"2024102101354455000_56.1.2000912.50","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.037382"},{"key":"2024102101354455000_56.1.2000912.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.09.045"},{"key":"2024102101354455000_56.1.2000912.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.04.001"},{"key":"2024102101354455000_56.1.2000912.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198144"},{"key":"2024102101354455000_56.1.2000912.54","doi-asserted-by":"crossref","unstructured":"AlGhatrif M , Cingolani O , Lakatta EG . The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science. JAMA Cardiol 2020; in press [ https:\/\/doi.org\/10.1001\/jamacardio.2020.1329 ].","DOI":"10.1001\/jamacardio.2020.1329"},{"key":"2024102101354455000_56.1.2000912.55","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1440-1681.1996.tb03073.x","article-title":"Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists","volume":"3","author":"Campbell","year":"1996","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"key":"2024102101354455000_56.1.2000912.56","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.32.3.387"},{"key":"2024102101354455000_56.1.2000912.57","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.72.2.312"},{"key":"2024102101354455000_56.1.2000912.58","doi-asserted-by":"crossref","unstructured":"Jurado-Palomo J , Caballero T . Pathophysiology of bradykinin-mediated angioedema: the role of the complement system. In: Kartal SP , Kutlubay Z , eds. A Comprehensive Review of Urticaria and Angioedema. Rijeka, IntechOpen, 2017; pp. 151\u2013176.","DOI":"10.5772\/67704"},{"key":"2024102101354455000_56.1.2000912.59","unstructured":"Bahat G . Angiotensin converting enzyme (ACE) inhibition may have a role in the symptoms and progression of COVID-19 infection. BMJ 2020; rapid response [ www.bmj.com\/content\/368\/bmj.m406\/rr-23 ]."},{"key":"2024102101354455000_56.1.2000912.60","doi-asserted-by":"crossref","unstructured":"van de Veerdonk F , Netea MG , van Deuren M , et al. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. Preprints 2020; preprint [ https:\/\/doi.org\/10.20944\/preprints202004.0023.v1 ].","DOI":"10.20944\/preprints202004.0023.v1"},{"key":"2024102101354455000_56.1.2000912.61","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1940.sp003850"},{"key":"2024102101354455000_56.1.2000912.62","first-page":"1280","article-title":"Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling","volume":"19","author":"Walters","year":"2017","journal-title":"Europace"},{"key":"2024102101354455000_56.1.2000912.63","doi-asserted-by":"crossref","unstructured":"Turner AJ . ACE2 cell biology, regulation, and physiological functions. In: Unger T , Steckelings UM , dos Santos RAS , eds. The Protective Arm of the Renin Angiotensin System (RAS). Boston, Academic Press, 2015; pp. 185\u2013189.","DOI":"10.1016\/B978-0-12-801364-9.00025-0"},{"key":"2024102101354455000_56.1.2000912.64","doi-asserted-by":"publisher","DOI":"10.1038\/nature00786"},{"key":"2024102101354455000_56.1.2000912.65","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.114322"},{"key":"2024102101354455000_56.1.2000912.66","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/HYPERTENSIONAHA.108.116137","article-title":"Angiotensin-converting enzyme 2: cardioprotective player in the renin-angiotensin system?","volume":"52","author":"Turner","year":"2008","journal-title":"Hypertension"},{"key":"2024102101354455000_56.1.2000912.67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461"},{"key":"2024102101354455000_56.1.2000912.68","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000237862.94083.45"},{"key":"2024102101354455000_56.1.2000912.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2013.08.003"},{"key":"2024102101354455000_56.1.2000912.70","doi-asserted-by":"crossref","unstructured":"Chen D , Li X , Song Q , et al. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020; preprint [ https:\/\/doi.org\/10.1101\/2020.02.27.20028530 ].","DOI":"10.1001\/jamanetworkopen.2020.11122"},{"key":"2024102101354455000_56.1.2000912.71","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2147\/COPD.S158634","article-title":"Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD","volume":"13","author":"Lai","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102101354455000_56.1.2000912.72","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis733"},{"key":"2024102101354455000_56.1.2000912.73","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03743"},{"key":"2024102101354455000_56.1.2000912.74","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/SHK.0000000000001067","article-title":"Soluble epoxide hydrolase plays a vital role in angiotensin II-induced lung injury in mice","volume":"50","author":"Tao","year":"2018","journal-title":"Shock"},{"key":"2024102101354455000_56.1.2000912.75","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-013-2920-9"},{"key":"2024102101354455000_56.1.2000912.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2007.03.075"},{"key":"2024102101354455000_56.1.2000912.77","first-page":"1739","article-title":"[Losartan regulates oxidative stress via caveolin-1 and NOX4 in mice with ventilator-induced lung injury]","volume":"35","author":"Ling","year":"2015","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"2024102101354455000_56.1.2000912.78","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000206107.92476.39"},{"key":"2024102101354455000_56.1.2000912.79","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00046106"},{"key":"2024102101354455000_56.1.2000912.80","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4266\/kjccm.2016.00976","article-title":"Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J Crit Care Med"},{"key":"2024102101354455000_56.1.2000912.81","doi-asserted-by":"publisher","DOI":"10.1186\/cc9317"},{"key":"2024102101354455000_56.1.2000912.82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SHK.0000000000001382","article-title":"Preadmission antihypertensive drug use and sepsis outcome: impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)","volume":"53","author":"Hsieh","year":"2020","journal-title":"Shock"},{"key":"2024102101354455000_56.1.2000912.83","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12.1619"},{"key":"2024102101354455000_56.1.2000912.84","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-166"},{"key":"2024102101354455000_56.1.2000912.85","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4595"},{"key":"2024102101354455000_56.1.2000912.86","first-page":"419","article-title":"Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia","volume":"31","author":"Henry","year":"2018","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2024102101354455000_56.1.2000912.87","doi-asserted-by":"crossref","first-page":"19840","DOI":"10.1038\/srep19840","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"2024102101354455000_56.1.2000912.88","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4594"},{"key":"2024102101354455000_56.1.2000912.89","doi-asserted-by":"publisher","DOI":"10.1038\/srep07027"},{"key":"2024102101354455000_56.1.2000912.90","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-015-4814-7"},{"key":"2024102101354455000_56.1.2000912.91","first-page":"3216","article-title":"[Effects of losartan on pulmonary dendritic cells in lipopolysaccharide-induced acute lung injury mice]","volume":"94","author":"Liu","year":"2014","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2024102101354455000_56.1.2000912.92","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1189\/jlb.68.5.700","article-title":"Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP","volume":"68","author":"Raiden","year":"2000","journal-title":"J Leukoc Biol"},{"key":"2024102101354455000_56.1.2000912.93","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-019-1182-0"},{"key":"2024102101354455000_56.1.2000912.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2008.03.004"},{"key":"2024102101354455000_56.1.2000912.95","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1643-8"},{"key":"2024102101354455000_56.1.2000912.96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"2024102101354455000_56.1.2000912.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.09.038"},{"key":"2024102101354455000_56.1.2000912.98","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2213-2600(20)30117-X","article-title":"Sex difference and smoking predisposition in patients with COVID-19","volume":"8","author":"Cai","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102101354455000_56.1.2000912.99","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.184986"},{"key":"2024102101354455000_56.1.2000912.100","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(16)30969-2","article-title":"Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure","volume":"389","author":"Packer","year":"2017","journal-title":"Lancet"},{"key":"2024102101354455000_56.1.2000912.101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46215"},{"key":"2024102101354455000_56.1.2000912.102","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00688-2020"},{"key":"2024102101354455000_56.1.2000912.103","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.burns.2015.04.010","article-title":"Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome","volume":"41","author":"Yilin","year":"2015","journal-title":"Burns"},{"key":"2024102101354455000_56.1.2000912.104","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102101354455000_56.1.2000912.105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00002018-199716010-00004","article-title":"A risk-benefit assessment of losartan potassium in the treatment of hypertension","volume":"16","author":"Burrell","year":"1997","journal-title":"Drug Saf"},{"key":"2024102101354455000_56.1.2000912.106","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.4.1333"},{"key":"2024102101354455000_56.1.2000912.107","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199504000-00001"},{"key":"2024102101354455000_56.1.2000912.108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb05696.x"},{"key":"2024102101354455000_56.1.2000912.109","first-page":"263","article-title":"Inhibitors of the renin-angiotensin system. Clinical pharmacology studies on kinetics, dynamics and concentration-effect relationships","volume":"43","author":"Reid","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"2024102101354455000_56.1.2000912.110","doi-asserted-by":"crossref","unstructured":"Liu Y , Huang F , Xu J , et al. Anti-hypertensive angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020; preprint [ https:\/\/doi.org\/10.1101\/2020.03.20.20039586 ].","DOI":"10.1101\/2020.03.20.20039586"},{"key":"2024102101354455000_56.1.2000912.111","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2024102101354455000_56.1.2000912.112","doi-asserted-by":"crossref","unstructured":"Bean DM , Kraljevic Z , Searle T , et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-COVID-19 infection in a multi-site UK acute Hospital Trust. medRxiv 2020; preprint [ https:\/\/doi.org\/10.1101\/2020.04.07.20056788 ].","DOI":"10.1101\/2020.04.07.20056788"},{"key":"2024102101354455000_56.1.2000912.113","doi-asserted-by":"crossref","unstructured":"Sallari Jazzi A , Mahnam K , Hossein Hejazi S , et al. Inhibition of viral macrodomain of COVID-19 and human TRPM2 by losartan. Preprints 2020; preprint [ https:\/\/doi.org\/10.20944\/preprints202003.0457.v1 ].","DOI":"10.20944\/preprints202003.0457.v1"},{"key":"2024102101354455000_56.1.2000912.114","unstructured":"International Society of Hypertension . A statement from the International Society of Hypertension on COVID-19. https:\/\/ish-world.com\/news\/a\/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19\/ Date last accessed: 30 March 2020."},{"key":"2024102101354455000_56.1.2000912.115","unstructured":"Hypertension Canada . Hypertension, ACE-inhibitors and angiotensin receptor blockers and COVID-19 . Markham, Hypertension Canada, 2020. https:\/\/hypertension.ca\/wp-content\/uploads\/2020\/03\/2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf"},{"key":"2024102101354455000_56.1.2000912.116","unstructured":"Canadian Cardiovascular Society . COVID-19 and concerns regarding use of ACEi\/ARB\/ARNi medications for heart failure or hypertension . Ottawa, Canadian Cardiovascular Society, 2020. www.conferenceharvester.com\/Uploads\/Documents\/9006\/CCSCHFSstatementregardingCOVID.pdf"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00912-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:32:31Z","timestamp":1740382351000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00912-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,7,9]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1183\/13993003.00912-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00912-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]}}}